WKWan Soo Kim

Wan Soo Kim

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Wan Soo Kim has a total of 22 co-authors. Here are the top co-authors by number of shared publications:

  • Hyun Jin Kim

    Department of Internal Medicine and Institute of Health Science, Gyeongsang National University School of Medicine, Jinju, Korea

    3 shared publications
  • Ok-Jae Lee

    Department of Internal Medicine, Gyeongsang National University Hospital, Gyeongsang National University College of Medicine, Jinju 52727, Republic of Korea

    3 shared publications
  • Sang Soo Lee

    Department of Internal Medicine, Gyeongsang National University School of Medicine and Gyeongsang National University Changwon Hospital, Changwon, Republic of korea

    3 shared publications
  • Woon Tae Jung

    Department of Internal Medicine Gyeongsang National University College of Medicine and Gyeongsang National University Hospital Jinju Republic of Korea

    3 shared publications
  • Chang Yoon Ha

    Department of Internal Medicine, Gyeongsang National University College of Medicine, Jinju 52727, Korea

    2 shared publications
  • Hong Jun Kim

    Department of Internal Medicine, Gyeongsang National University School of Medicine and Gyeongsang National University Hospital, Jinju

    2 shared publications

Latest Publications

  • Open Access

    Hepatitis C virus genotype affects survival in patients with hepatocellular carcinoma

    by Hye Kyong Park, Sang Soo Lee, Chang Bin Im, Changjo Im, Ra Ri Cha, Wan Soo Kim, Hyun Chin Cho, Jae Min Lee, Hyun Jin Kim, Tae Hyo Kim, et al.

    There is currently no evidence that hepatitis C virus (HCV) genotype affects survival in patients with hepatocellular carcinoma (HCC). This study aimed to investigate whether the HCV genotype affected the survival rate of patients with HCV-related HCC. We performed a retrospective cohort study using the data of patients with HCV-related HCC evaluated at two centers in Korea between January 2005 and December 2016. Propensity score matching between genotype 2 patients and non-genotype 2 patients was performed to reduce bias. A total of 180 patients were enrolled. Of these, 86, 78, and 16 had genotype 1, genotype 2, and genotype 3 HCV-related HCC, respectively. The median age was 66.0 years, and the median overall survival was 28.6 months. In the entire cohort, patients with genotype 2 had a longer median overall survival (31.7 months) than patients with genotype 1 (28.7 months; P = 0.004) or genotype 3 (15.0 months; P = 0.003). In the propensity score–matched cohort, genotype 2 patients also showed a better survival rate than non-genotype 2 patients (P = 0.007). Genotype 2 patients also had a longer median decompensation-free survival than non-genotype 2 patients (P = 0.001). However, there was no significant difference in recurrence-free survival between genotype 2 and non-genotype 2 patients who underwent curative treatment (P = 0.077). In multivariate Cox regression analysis, non-genotype 2 (hazard ratio, 2.19; 95% confidence interval, 1.29–3.71) remained an independent risk factor for death. Among patients with HCV-related HCC, those with genotype 2 have better survival.


  • Open Access

    Clinical features and outcomes of abdominal tuberculosis in southeastern Korea: 12 years of experience

    by Jin-Kyu Cho, Young Min Choi, Sang Soo Lee, Hye Kyong Park, Ra Ri Cha, Wan Soo Kim, Jin Joo Kim, Jae Min Lee, Hong Jun Kim, Chang Yoon Ha, et al.

    Abdominal tuberculosis (TB) is an uncommon form of infection with Mycobacterium tuberculosis in Korea. In this study, we aimed to highlight the clinical features, diagnostic methods, and outcomes of abdominal TB over 12 years in Southeastern Korea. A total of 139 patients diagnosed as having abdominal TB who received anti-TB medication from January 2005 to June 2016 were reviewed. Among them, 69 patients (49.6%) had luminal TB, 28 (20.1%) had peritoneal TB, 7 (5.0%) had nodal TB, 23 (16.5%) had visceral TB, and 12 (8.6%) had mixed TB. The most frequent symptoms were abdominal pain (34.5%) and abdominal distension (21.0%). Diagnosis of abdominal TB was confirmed using microbiologic and/or histologic methods in 76 patients (confirmed diagnosis), while the remaining 63 patients were diagnosed based on clinical presentation and radiologic imaging (clinical diagnosis). According to diagnostic method, frequency of clinical diagnosis was highest in patients with luminal (50.7%) or peritoneal (64.3%) TB, while frequency of microscopic diagnosis was highest in patients with visceral TB (68.2%), and frequency of histologic diagnosis was highest in patients with nodal TB (85.2%). Interestingly, most patients, except those with nodal TB, showed a good response to anti-TB agents, with 84.2% showing a complete response. The mortality rate was only 1.4% in the present study. Most patients responded very well to anti-TB therapy, and surgery was required in only a minority of cases of suspected abdominal TB.


  • Open Access

    Hepatitis C and not Hepatitis B virus is a risk factor for anti-tuberculosis drug induced liver injury

    by Wan Soo Kim, Sang Soo Lee, Chang Min Lee, Hong Jun Kim, Chang Yoon Ha, Hyun Jin Kim, Tae Hyo Kim, Woon Tae Jung, Ok Jae Lee, Jeong Woo Hong, et al.

    The risk of anti-tuberculosis (TB) drug-induced liver injury (DILI) in patients with chronic viral hepatitis (CVH) is not clear. The aim of this study was to investigate incidence and risk factors associated with TB DILI in CVH and non-CVH patients. Retrospectively, a total of 128 CVH patients who received anti-TB medication from January 2005 to February 2014 were reviewed. Among these, 83 patients had hepatitis B virus (HBV), 41 patients had hepatitis C virus (HCV) and 4 patients were dual hepatitis B and hepatitis C virus co-infected (HBV + HCV) with 251 non-CVH patients who received anti-TB medication selected as the controls. There were no human immunodeficiency virus co-infected patients. Risk factors for DILI were analyzed using cox regression analysis. The incidence of DILI was significantly higher in the HCV group (13/41 [31.7 %], p < 0.001) and HBV + HCV groups (3/4 [75.0 %], p = 0.002) compared to the control group (25/251 [10.0 %]). The incidence of transient liver function impairment in the hepatitis B virus group was higher than in the control group (18/83 [21.7 %] vs. 27/251 [10.8 %] p = 0.010), but not in DILI (11/83 [13.3 %] vs. 25/251 [10.0 %], p = 0.400). In total patients, HCV, HBV + HCV co-infection, older age, and baseline liver function abnormality were independent factors of DILI. It is recommended to carefully monitor for DILI in patients with HCV or HBV/HCV co-infection, older age, and baseline liver function abnormality.